查詢結果分析
來源資料
頁籤選單縮合
題名 | 肺癌的免疫治療=Immunotherapy of Lung Cancer |
---|---|
作者姓名(中文) | 鄭舒帆; 鄭高珍; | 書刊名 | 內科學誌 |
卷期 | 29:3 2018.06[民107.06] |
頁次 | 頁153-159 |
分類號 | 415.468 |
關鍵詞 | 肺癌; 免疫治療; 檢查點抑制劑; Lung cancer; Immunotherapy; Checkpoint inhibitors; PD-1 inhibitor; Programmed cell death 1 inhibitor; Programmed cell death-ligand 1 inhibitor; |
語文 | 中文(Chinese) |
中文摘要 | 肺癌在105年躍居為台灣十大死因中惡性腫瘤的第一位,讓各界越來越重視肺癌的發生與治療。從過去的根除性手術治療、電療、化學治療和標靶治療都成功延長了許多肺癌病人的生命也改善了許多病人的症狀。但隨著醫學的進步,科學家和腫瘤專家不斷研究免疫系統與腫瘤之間一系列的互動機轉,試圖找出腫瘤細胞抑制免疫系統清除的機轉並將以逆轉,重新激活免疫系統的活性來對抗腫瘤細胞。促使了免疫治療藥物的出現,也將癌症治療帶入了免疫治療的時代。目前免疫治療在肺癌的治療中取得了不錯的成效。本文將介紹目前台灣核准使用針對肺癌的免疫治療藥物、機轉、使用條件以及目前臨床實驗的成果。 |
英文摘要 | Lung cancer is the leading cause of cancer-related death in Taiwan now a day. The incidence and treatment strategy of lung cancer became the major issue of society. The management of lung cancer including curative surgery, radiation therapy, chemotherapy and target therapy which improved the patient’s long term survival and the clinical symptoms. Investigation of the relationship between the tumor cells environment with the human immune system and the development of the inhibition mechanism to the immune system by tumor cells promote the arise of Immunotherapy, bringing the treatment of lung cancer into the new era of immunotherapy. We will introduce the development of the immunotherapy of the lung cnacer, current available immunotherapy in Taiwan and their clinical studies result. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。